ImpediMed lodges 2026 Corporate Governance Statement and Appendix 4G
I'm LongbridgeAI, I can summarize articles.ImpediMed Limited (ASX: IPD) has lodged its 2026 Corporate Governance Statement and Appendix 4G, approved by the board on August 27, 2026. This filing fulfills ASX requirements for corporate governance reporting, enhancing transparency and regulatory compliance for shareholders. The company, a medical technology firm specializing in bioimpedance devices, continues to adhere to listed entity standards. Current analyst sentiment remains mixed, with a 'Buy' rating but a low price target of A$0.01, alongside a technical 'Sell' signal.
Impedimed Limited ( (AU:IPD) ) has shared an update.
ImpediMed Limited has released its Appendix 4G and updated Corporate Governance Statement for the financial year ended 30 June 2026, confirming that these disclosures are available on its website and have been approved by the board as at 27 August 2026. The lodgement fulfils ASX requirements around corporate governance reporting and verification, underscoring the company’s adherence to listed entity governance standards and providing investors with clearer insight into its compliance and oversight practices.
The governance statement outlines the extent to which ImpediMed follows ASX Corporate Governance Council recommendations, and the Appendix 4G serves as a key for locating those disclosures and ensuring they meet Listing Rule obligations. This formal update supports transparency for shareholders and other stakeholders, reinforces regulatory compliance, and may strengthen market confidence in the company’s governance framework and reporting discipline.
The most recent analyst rating on (AU:IPD) stock is a Buy
with a A$0.01 price target.
To see the full list of analyst forecasts on Impedimed Limited stock,
see the AU:IPD Stock Forecast page.
More about Impedimed Limited
ImpediMed Limited (ASX: IPD) is an Australian medical technology company that develops bioimpedance spectroscopy devices and software used to assess body composition and fluid status, with applications in the monitoring of conditions such as lymphedema. The company targets healthcare providers and hospitals, operating within the broader medtech and diagnostics market and is subject to ASX corporate governance and disclosure requirements.
Technical Sentiment Signal: Sell
Current Market Cap: A$18.31M
Find detailed analytics on IPD stock on TipRanks’ Stock Analysis page.